Gary Richardson

7.5k citations
112 papers · 3.9k · 2 hit papers · h-index 20

Impact in

  • Oncology top 1%
    • Colorectal Cancer Treatments and Studies
    • Bone health and treatments
    • Lung Cancer Research Studies
    • Cancer Treatment and Pharmacology
  • Hepatology top 5%
    • Hepatocellular Carcinoma Treatment and Prognosis

Papers in

    • Colorectal Cancer Treatments and Studies 11
    • Lung Cancer Research Studies 11
    • Cancer Treatment and Pharmacology 11
    • HER2/EGFR in Cancer Research 9
    • Cancer Immunotherapy and Biomarkers 9
    • Lung Cancer Treatments and Mutations 14

Gary Richardson

105 papers receiving 3.8k citations

Gary Richardson's Hit Papers

Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials 2012 · 428 citations
4280+6+12Years since publication50010001.5k

Peers

Gary Richardson
Comparison fields: 5 of 110
  • Oncology 2.2k
  • Hepatology 216
  • Pulmonary and Respiratory Medicine 839
  • Cancer Research 339
  • Pathology and Forensic Medicine 323
Replace Shenhong Wu with:
Shenhong Wu United States
Peter D. Eisenberg United States
Francisco Vera-Badillo Canada
Roberto Petrioli Italy
Mark Kozloff United States
Per Pfeiffer Denmark
Barry C. Lembersky United States
Mary Cabiddu Italy
Jean‐François Morère France
Giacomo Cartenì Italy
Gary Richardson relative to Shenhong Wu United States Shenhong Wu's profile →
Citations per field
00.5×1.5×
Shenhong Wu · 1×
Citations per year

Countries citing papers authored by Gary Richardson

Since Specialization
Citations

This map shows the geographic impact of Gary Richardson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gary Richardson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gary Richardson more than expected).

Fields of papers citing papers by Gary Richardson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gary Richardson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gary Richardson. The network helps show where Gary Richardson may publish in the future.

Co-authors

The 25 scholars most cited alongside Gary Richardson, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Gary Richardson Line = papers co-authored together Gary Richardson links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 112 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer
Hit paper breakdown →
20071520
2
Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials
Hit paper breakdown →
2012428
3 2000230
4 1993189
5 2001175
6 2011171
7 1998144
8 201584
9 200475
10 200054
11 199752
12 199546
13 201341
14 200433
15 199231
16 200527
17 201325
18 201021
19 199320
20 202119

About Gary Richardson

Gary Richardson is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging, Cancer Research and Reproductive Medicine, having authored 112 papers that have together received 3.9k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (14 papers), Ovarian cancer diagnosis and treatment (11 papers), Monoclonal and Polyclonal Antibodies Research (11 papers), Colorectal Cancer Treatments and Studies (11 papers), Lung Cancer Research Studies (11 papers), Cancer Treatment and Pharmacology (11 papers), HER2/EGFR in Cancer Research (9 papers) and Cancer Immunotherapy and Biomarkers (9 papers). The work is most often cited by research in Oncology (2.2k citations), Hepatology (216 citations), Pulmonary and Respiratory Medicine (839 citations), Cancer Research (339 citations) and Pathology and Forensic Medicine (323 citations). Gary Richardson has collaborated with scholars based in Australia, United States and China. Frequent co-authors include Salvatore Siena, Michael Wolf, Rafael G. Amado, Yves Humblet, Jean–Luc Van Laethem, Joan Maurel, Eric Van Cutsem, Alain Hendlisz, Jean-Luc Canon and Bart Neyns. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Cancer Research, Bone Marrow Transplantation and European Journal of Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact